Amycretin is still in trials. It does not appear to be approved as a medicine in Europe or the United States, so there is nothing for a tracker to record yet. This page is here to answer that directly rather than leave a gap for someone else to fill.
What the name refers to
Amycretin is a compound Novo Nordisk A/S has in development. A study involving it is registered on the public trial registry, which records that research is happening and nothing about what it has found.
There is no label and no authorised form, and this page carries none of the detail the rest of this section carries for medicines that exist.
This one is earlier than the others
Amycretin has a much thinner public record than the other names people ask about: a single registered study rather than dozens. Early research is where the gap between what is written about something and what is actually known about it is widest.
Which is a reason to say less rather than more. The status below is what we checked and when.
Can I track Amycretin in Veya?
Not yet, because there is no approved medicine to record. If that changes, this page gets rewritten around it and Veya records it like any other.
Why does this page not tell me about the research?
Veya does not describe what any medicine does, approved or otherwise. Research findings need someone who can weigh them against your own circumstances, which a web page cannot do.
When will it be available?
We do not know, and guessing would be no use to you. The status block above gives the date we last looked and what we found.
Is Veya connected to Novo Nordisk?
No. Veya is provider-neutral and independent. It does not sell, supply or prescribe medication, and it is not affiliated with any manufacturer. The name appears here only to identify what this page is about.
What can I use Veya for in the meantime?
If you are already on an approved GLP-1 medicine, Veya keeps a record of when you took it and what followed. Those pages are linked below.